Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bluejay DiagnosticsBJDX -5.82%22 3-Year EBITDA Growth Rate is 88.20% as of Jun. 2026, which is 16% above its 10-year median of 75.80. GuruFocus rates BJDX with a GF Score™ of 22/100. The stock has 1 warning sign investors should review. Among 690 Medical Devices & Instruments companies, Bluejay Diagnostics ranks better than 97.54% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 88.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Bluejay Diagnostics was 88.20% per year. The lowest was 63.40% per year. And the median was 75.80% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Bluejay Diagnostics 3-Year EBITDA Growth Rate Related Terms
BJDX vs VTAK, PFSA, RBOT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Bluejay Diagnostics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bluejay Diagnostics 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Bluejay Diagnostics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 88.20% mean?
Bluejay Diagnostics (BJDX) has a 3-Year EBITDA Growth Rate of 88.20% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bluejay Diagnostics and its competitors. This is 16% above median its historical median of 75.80. Over the past decade, Bluejay Diagnostics' 3-Year EBITDA Growth Rate has ranged from 63.40 to 88.20. According to the industry distribution chart, Bluejay Diagnostics ranks #17 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 2.5%.
Is Bluejay Diagnostics' 3-Year EBITDA Growth Rate too high?
Bluejay Diagnostics' current 3-Year EBITDA Growth Rate of 88.20% is 16% above median its 10-year median of 75.80. Over the past 10 years, this metric has ranged from a low of 63.40 to a high of 88.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Bluejay Diagnostics' value of 88.20% is 975.6% above this industry median. Based on the distribution chart, Bluejay Diagnostics ranks #17 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bluejay Diagnostics has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Bluejay Diagnostics' 3-Year EBITDA Growth Rate compare to VTAK and PFSA?
According to the Medical Devices & Instruments industry distribution chart, Bluejay Diagnostics ranks #17 out of 690 companies for 3-Year EBITDA Growth Rate. This places Bluejay Diagnostics in the top 3% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.20. Bluejay Diagnostics' value of 88.20% is 975.6% above this benchmark. Historically, Bluejay Diagnostics' own 3-Year EBITDA Growth Rate has ranged from 63.40 to 88.20 over the past decade. While the company's 10-year median is 75.80 vs. the industry median of 8.20, Bluejay Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bluejay Diagnostics's current 3-Year EBITDA Growth Rate of 88.20% is 975.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Bluejay Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bluejay Diagnostics's current 3-Year EBITDA Growth Rate is 88.20%, which is 16% above median its own 10-year median of 75.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bluejay Diagnostics stock overvalued right now?
Bluejay Diagnostics (BJDX) has a current 3-Year EBITDA Growth Rate of 88.20%. The current 3-Year EBITDA Growth Rate is 88.20%, which is 16% above median its 10-year median of 75.80 and 975.6% above the Medical Devices & Instruments industry median of 8.20. Bluejay Diagnostics' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Bluejay Diagnostics (BJDX), the current 3-Year EBITDA Growth Rate is 88.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and quicker triage/treatment decisions.
22GF Score
Get the complete analysis for BJDX
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJDX has been successfully added to your 
